InvestorsHub Logo
Followers 0
Posts 749
Boards Moderated 0
Alias Born 09/14/2017

Re: doogdilinger post# 33853

Tuesday, 03/27/2018 9:05:15 AM

Tuesday, March 27, 2018 9:05:15 AM

Post# of 38634

Yep IMO the ongoing severe lack of success on SeroquelXR commercialization has been the biggest disappointment of all over the past year!



You are right. I expected more too. Unfortunately.

We have to think what they should do now. My opinion is, they should combine Focalin and PODRAS. Maybe Seroquel and PODRAS too.

What I mean, they should make two new products taking two old and already marketed products and combine them with PODRAS.

This would be best way to make PODRAS technology accepted by FDA. This would give several benefits. First neither of these products would have direct competition, because there would not be anything like them marketed before. Second issue is, they can set them different price. Not the same present products without PODRAS have. Third and most important is, this would be easiest way to have PODRAS technology accepted by FDA. All they have to do is proving the drugs with or without PODRAS have same effect, but the other one has overdose prevention.

And yes - I have sent the same thoughts to Odidis, Patient and Akyempon too. I just hope they have enough cash to make new products Focalin PODRAS and Seroquel PODRAS.

I very much doubt MNK would not be the best partner to sell Seroquel PODRAS. Maybe they can find an other.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y